Baxter sinks on more propofol trouble
This article was originally published in Scrip
Baxter International saw more than a billion dollars wiped off its value on 12 October on news that, together with partner Teva Pharmaceutical Industries, it had to pay a further $90 million to an individual in punitive damages for selling reusable vials of the anaesthetic propofol that was blamed for colonoscopy patients contracting hepatitis C some years ago.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.